Eli Lilly (LLY) has demonstrated strong performance over the past decade. Although its stock price has experienced a correction of approximately 8% over the past 12 months due to clinical research setbacks and market volatility, this is more likely a temporary downturn. From a long-term perspective, Eli Lilly’s fundamentals remain solid, and the current stock price even appears to have undervalued potential.
Looking solely at the price-to-earnings ratio, Eli Lilly’s valuation of 27 times is indeed higher than the healthcare industry’s average of 17.5 times. However, this is not the full picture. This premium is built upon the company’s exceptional growth capabilities. Over the past two years, Eli Lilly has demonstrated revenue growth momentum far surpassing its peers, which is rare for a company of its scale. In this field, only its long-term competitor Novo Nordisk can be compared, and Eli Lilly now holds a significant lead. This indicates that the company has proven its ability to consistently outperform the industry average, providing solid support for its premium valuation.
Eli Lilly’s future growth is driven by strong forces, with the explosive growth of the weight management drug market being key. Increasing societal focus on health issues has led to a surge in demand for weight-loss drugs, and Eli Lilly is at the forefront of this wave. Its blockbuster drug Tirzepatide (brand name Zepbound), just three years after launch, has already exceeded sales expectations, reaching $14.7 billion in the first half of this year alone. Early peak sales forecasts have been left far behind, with new projections suggesting sales could approach $62 billion by 2030, potentially making it a phenomenal exclusive product.
Furthermore, pipeline diversification constitutes another pillar of growth. The upcoming oral GLP-1 drug, Orforglipron, has shown excellent results in late-stage clinical trials, successfully addressing some of the shortcomings of injectable drugs. For patients who prefer oral medications or are price-sensitive, it offers a more convenient and potentially more economical option. Orforglipron’s sales are projected to potentially reach $12.7 billion by 2030. The synergistic effects of products like Tirzepatide and Orforglipron are propelling Eli Lilly towards its goal of becoming the world’s top-selling pharmaceutical company.
In addition to its strong growth narrative, Eli Lilly has also demonstrated reliability in shareholder returns, with its dividend program being particularly noteworthy. The company utilizes its robust cash flow to consistently reward shareholders, having doubled its dividend over the past five years. Although its dividend yield of 0.7% is below the market average, its payout ratio of 37% remains within a healthy and sustainable range, leaving ample room for future dividend growth. This is an attractive trait for investors seeking both income and capital appreciation.
Although Eli Lilly’s stock price has retreated from its 2024 highs, and some traditional valuation metrics indicate it is not “cheap,” a deeper look into its growth potential reveals that the current valuation appears justified. Eli Lilly is not just a good company – it possesses core products with patent protection until the mid-2030s, a promising R&D pipeline, and a history of exceptional operational performance. For long-term investors, Eli Lilly, with its clear growth trajectory and sound financial policies, remains a high-quality choice worthy of attention.
